LifeSci Capital Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $75
Oppenheimer Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $104
Leerink Partners Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $73
Jefferies Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Cuts Target Price to $65
A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $55 to $100
MoonLake Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), MoonLake Immunotherapeutics (MLTX) and Protara Therapeutics (TARA)
MoonLake Immunotherap Price Target Maintained With a $100.00/Share by HC Wainwright & Co.
Buy Rating Affirmed for MoonLake Immunotherapeutics Amid Promising Hidradenitis Suppurativa Treatment Prospects
Barclays Sticks to Their Hold Rating for MoonLake Immunotherapeutics (MLTX)
MoonLake Analyst Ratings
Wolfe Research Downgrades MoonLake Immunotherapeutics(MLTX.US) to Hold Rating
Barclays Keeps Their Hold Rating on MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics (MLTX) Receives a Buy From TD Cowen
MoonLake Analyst Ratings
MoonLake Analyst Ratings
MoonLake Analyst Ratings
MoonLake Analyst Ratings
Buy Rating Reaffirmed for MoonLake Immunotherapeutics Amidst Promising Clinical Trials and Strategic Development Plans
MoonLake Immunotherapeutics Buy Rating Justified by Strong Clinical Execution and Financial Position